Posts

Posted on

Over 50% of Americans Worry About the Financial Implications of a Natural Disaster According to a ValuePenguin.com Survey

Over 60% of homeowners in hurricane-prone areas don’t have or don’t know if they have flood insurance.

PR Newswire

NEW YORK, Sept. 15, 2021 /PRNewswire/ — Natural disasters have Americans more than worried about just climate change. Some fear a natural disaster or emergency could financially devastate them. Especially as emergencies and natural continue to pile up. 

According to a survey conducted by ValuePenguin, over 50% of consumers fear that an emergency or natural disaster would be too expensive for them to afford. 

Key findings:

View full report: https://www.valuepenguin.com/how-prepared-are-americans-for-emergencies

About ValuePenguin.com: ValuePenguin.com, part of LendingTree (NASDAQ: TREE), is a personal finance website that conducts in-depth research and provides objective analysis to help guide consumers to the best financial decisions. ValuePenguin focuses on value, assessing whether the return of a particular decision is worth the cost or risk of that option, and how this stacks up with the other possible choices they may have. For more information, please visit www.valuepenguin.com, like our Facebook page, or follow us on Twitter @ValuePenguin.

Media Contact:
Nadia Gonzalez 
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/over-50-of-americans-worry-about-the-financial-implications-of-a-natural-disaster-according-to-a-valuepenguincom-survey-301377188.html

SOURCE ValuePenguin.com

Posted on

Yext’s AI Search-Powered Website Wins 2021 WebAward for Outstanding Website

The site is powered by the company’s revolutionary AI search technology, making it faster, more responsive, and more accessible.

PR Newswire

NEW YORK, Sept. 15, 2021 /PRNewswire/ — Yext, Inc. (NYSE: YEXT), the AI Search Company, today announced that its website, www.yext.com, won a 2021 WebAward for Outstanding Website.

Evaluated on criteria including design, innovation, content, technology, and ease of use, the site was praised by WebAward judges as “clean, elegant, easy to navigate, [and] beautifully designed,” with “a wealth of information, logical structure, [and] innovative solutions.”

“We’re incredibly honored for yext.com to be recognized by the WebAwards,” said Josh Grau, Chief Marketing Officer at Yext. “When it came to the redesign of our own website, we wanted to practice what we preach by marrying a creative aesthetic with the power of our AI search. The result is something we’re proud of: a brand experience that is bold and differentiated, and a user experience that is streamlined and search-forward.”

Earlier this year, Yext set out to redevelop and redesign its website from the ground up — and completely in-house — in order to improve the experiences of customers, prospects, investors, and job candidates. To revamp its look and feel, the company built an entirely custom design system for the site. Under the hood, it transitioned the site to its own revolutionary AI search technology, enabling it to be faster, more responsive, and more accessible.

Founded by the Web Marketing Association and now in its 17th year, the WebAwards are the longest-running annual website award competition, dedicated to setting the standard of excellence for website development and recognizing the best websites in almost 100 industry categories.


Visit Yext’s award-winning homepage here.

About Yext


Yext
 (NYSE: YEXT) is the AI Search Company and is on a mission to transform the enterprise with AI search.

With the explosion of information and data online, search has never been more important. However, while the world of consumer search has innovated over time, enterprise search has not. In fact, the majority of enterprise search is powered by outdated keyword search technology that only scans for keywords and delivers a list of hyperlinks rather than actually answering questions.

Yext, the AI Search Company, offers a modern, AI-powered Answers Platform that understands natural language so that when people ask questions about a business online they get direct answers – not links.

Brands like Verizon, Vanguard, Subway and Marriott — as well as organizations like the U.S. State Department and World Health Organization — trust Yext to radically improve their business with answers-led AI search.

CONTACT: Amanda Kontor, [email protected]

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/yexts-ai-search-powered-website-wins-2021-webaward-for-outstanding-website-301376927.html

SOURCE Yext, Inc.

Posted on

GT Biopharma Announces Updated Positive Safety Data From Phase 1 GTB-3550 Monotherapy TriKE™ Trial an Investigational Immunotherapy for Refractory Cancers to be Presented at ESMO Congress 2021

– Abstract presented by Jeffrey Miller, MD, University of Minnesota Medical School Professor of Medicine, Division of Hematology, Oncology and Transplantation

– The mini-oral presentation highlights updated safety results from a Phase 1 GTB-3550 TriKE trial as a potential targeted therapy in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing Her2 or B7H3

PR Newswire

BEVERLY HILLS, Calif., Sept. 15, 2021 /PRNewswire/ — GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE protein biologic technology platform, today announced that Jeffrey Miller, MD, University of Minnesota Medical School, Professor of Medicine, Division of Hematology, Oncology and Transportation will present a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2021 to be held virtually September 16-21.

The mini-oral presentation will present updated positive Phase 1 safety data, progress, and preclinical data going beyond hematologic malignancies to solid tumors of a Phase 1 GTB-3550 TriKE trial. The Tri-Specific Killer Engager TriKE program is currently in pre-clinical and clinical development for the treatment of relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS) with solid tumor TriKE commercial manufacturing and IND enabling studies in progress.

Mini-oral Poster Presentation Details:

Title: GTB-3550 TriKE safely activates and delivers IL-15 to NK cells, but not T cells, in immune suppressed patients with advanced myeloid malignancies, a novel paradigm exportable to solid tumors expressing Her2 or B7H3 (Abstract #4068)

Speaker: Jeffrey Miller, MD

Mini-oral Session: Investigational Immunotherapy (Channel 2)

Presentation Time: September 17 at 6:10 PM EST

Mini-oral Presentation Number: 965MO

The abstract is currently available on the ESMO website at www.esmo.org. At the start of the mini-oral session the presentation will be available in the “Presentations” section of the Company’s website at https://www.gtbiopharma.com.

Recent Announcement
The Company recently announced the advancement of GTB-3650 into IND-enabling studies, with which it plans to supplant the ongoing Phase 1 program with GTB-3550. GTB-3650 is a novel molecule based on camelid single-domain camelid antibody technology with advantages that build upon the strong proof-of-concept data from the Company’s first generation TriKE program, GTB-3550.

Therapeutic and commercial advantages of GTB-3650 compared to GTB-3550 include:

  • Based on second generation camelid single-domain antibody technology that holds several advantages over traditional IgG monoclonal antibodies
  • Improved potency and enhanced binding affinity
  • Similar preclinical safety profile
  • Commercial manufacturing capabilities through arrangement with Cytovance
  • Proprietary patented molecule, which unlike GTB-3550, is wholly owned by GT Biopharma

About Camelid Antibodies

Camelid antibodies are single domain antibodies (sdAbs) from the Camelidae family of mammals that include llamas, camels, and alpacas. These animals produce 2 main types of antibodies. One type of antibody camelids produce is the conventional antibody that is made up of 2 heavy chains and 2 light chains. They also produce another type of antibody that is made up of only 2 heavy chains and no light chain. This is known as heavy chain IgG (hcIgG). While these antibodies do not contain the CH1 region, they retain an antigen binding domain called the VHH region. VHH antibodies, also known as single domain antibodies, contain only the VHH region from the camelid antibody. Camelid antibodies have key characteristics, which include high affinity and specificity (equivalent to conventional antibodies), high thermostability, good solubility and strictly monomeric behavior, small size, relatively low production cost, ease of genetic engineering, format flexibility or modularity, low immunogenicity, and a higher penetration rate into tissues.

About GTB-3650

GTB-3650 is the Company’s lead second-generation Tri-Specific Killer Engager TriKE® program currently in preclinical development for the treatment of relapsed/refractory acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

About GT Biopharma, Inc.

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict, including statements regarding the potential acquisition, the likelihood of closing the potential transaction, our clinical focus, and our current and proposed trials.  Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes”, “hopes”, “intends”, “estimates”, “expects”, “projects”, “plans”, “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking.  Our forward-looking statements are not a guarantee of performance, and actual results could differ materially from those contained in or expressed by such statements.  In evaluating all such statements, we urge you to specifically consider the various risk factors identified in our Annual Report on Form 10-K for the year ended December 31, 2020, our subsequent current reports on Form 8-K, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, and our other filings with the Securities and Exchange Commission, any of which could cause actual results to differ materially from those indicated by our forward-looking statements.

Our forward-looking statements reflect our current views with respect to future events and are based on currently available financial, economic, scientific, and competitive data and information on current business plans.  You should not place undue reliance on our forward-looking statements, which are subject to risks and uncertainties relating to, among other things:  (i) the sufficiency of our cash position and our ongoing ability to raise additional capital to fund our operations, (ii) our ability to complete our contemplated clinical trials, or to meet the FDA’s requirements with respect to safety and efficacy, (iii) our ability to identify patients to enroll in our clinical trials in a timely fashion, (iv) our ability to achieve approval of a marketable product, (v) design, implementation and conduct of clinical trials, (vii) the results of our clinical trials, including the possibility of unfavorable clinical trial results, (vii) the market for, and marketability of, any product that is approved, (viii) the existence or development of treatments that are viewed by medical professionals or patients as superior to our products, (ix) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, and social conditions, and (x) various other matters, many of which are beyond our control.  Should one or more of these risks or uncertainties develop, or should underlying assumptions prove to be incorrect, actual results may vary materially and adversely from those anticipated, believed, estimated, or otherwise indicated by our forward-looking statements.

We intend that all forward-looking statements made in this press release will be subject to the safe harbor protection of the federal securities laws pursuant to Section 27A of the Securities Act, to the extent applicable.  Except as required by law, we do not undertake any responsibility to update these forward-looking statements to take into account events or circumstances that occur after the date of this press release.  Additionally, we do not undertake any responsibility to update you on the occurrence of any unanticipated events which may cause actual results to differ from those expressed or implied by these forward-looking statements.

TriKE®is a registered trademark owned by GT Biopharma, Inc. 

Contacts:

Investor Relations:                                     
David Castaneda                                         
[email protected]                          
414-351-9758 

LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
212-915-2577                                          

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/gt-biopharma-announces-updated-positive-safety-data-from-phase-1-gtb-3550-monotherapy-trike-trial-an-investigational-immunotherapy-for-refractory-cancers-to-be-presented-at-esmo-congress-2021-301376916.html

SOURCE GT Biopharma, Inc.

Posted on

Altus Power, Inc., a Market-Leading Clean Electrification Company, Announces New Office Space in Stamford, Connecticut to Accommodate its Growing Team

PR Newswire

GREENWICH, Conn., Sept. 15, 2021 /PRNewswire/ — Altus Power, Inc. (“Altus Power” or the “Company”) today announced that it has signed a 10-year, 33,000 square-foot lease at 2200 Atlantic Street in Stamford, CT. With the move, Altus Power will relocate its headquarters from Greenwich, CT to Stamford, CT, increasing the size of its office space significantly to accommodate its growing team.

Altus Power’s employee base has grown by 50% this year, and the Company anticipates sustained growth

Altus Power previously announced an agreement for a business combination with CBRE Acquisition Holdings, Inc. (NYSE: CBAH), which is expected to result in Altus Power becoming a public company listed on the New York Stock Exchange.

Altus Power’s employee base has grown by 50% this year, and the Company anticipates sustained growth with open roles in software development, project management, construction, asset management, finance, and several other areas. See https://altuspower.com/careers/.

Altus Power’s new office space in Stamford is within walking distance to the metro station as well as restaurants, shops, cafes, breweries and the waterfront marina.

“With the rapidly increasing demand for clean energy, Altus Power has extremely ambitious goals for the next few years, and we intend to attract and retain best-in-class talent to help us execute. Our new office space provides us and our team with the perfect platform in support of current and future growth and an environment where we can continue to create and innovate for the benefit of our customers and stakeholders,” said Lars Norell, Co-CEO of Altus Power.

Altus Power was represented in the lease negotiations by CBRE, Inc.

About Altus Power

Altus Power, based in Greenwich, Connecticut, is creating a clean electrification ecosystem, serving its commercial, public sector and community solar customers with locally-sited solar generation, energy storage, and EV-charging stations across the U.S. Since its founding in 2009, Altus Power has developed or acquired in excess of 340 megawatts from Vermont to Hawaii. Visit altuspower.com to learn more.

About CBRE Acquisition Holdings, Inc.

CBRE Acquisition Holdings, Inc. (“CBAH”) is a blank-check company formed solely for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. CBAH is sponsored by CBRE Acquisition Sponsor, LLC, which is a subsidiary of CBRE Group, Inc.

No Offer or Solicitation

This communication is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the planned business combination between Altus Power and CBAH (the “Business Combination”) and the other transactions contemplated by the business combination agreement entered into by Altus Power and CBAH (the “Business Combination Agreement”) and shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Important Information About the Business Combination and Where to Find It

CBAH has filed with the U.S. Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4 (the “Registration Statement”), which includes a preliminary proxy statement/prospectus in connection with the proposed Business Combination and will mail a definitive proxy statement/prospectus and other relevant documents to its stockholders. CBAH’s stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus, and amendments thereto, and the definitive proxy statement/prospectus in connection with CBAH’s solicitation of proxies for its stockholders’ meeting to be held to approve the Business Combination because the proxy statement/prospectus will contain important information about CBAH, Altus Power and the Business Combination. The definitive proxy statement/prospectus will be mailed to stockholders of CBAH as of a record date to be established for voting on the Business Combination. Stockholders will also be able to obtain copies of the Registration Statement and the proxy statement/prospectus, without charge, once available, at the SEC’s website at www.sec.gov or by directing a request to CBRE Acquisition Holdings, Inc., 2100 McKinney Avenue, Suite 1250, Dallas, TX 75201.

Participants in the Solicitation

CBAH, Altus Power and certain of their respective directors and officers may be deemed participants in the solicitation of proxies of CBAH’s stockholders with respect to the approval of the Business Combination. CBAH and Altus Power urge investors, stockholders and other interested persons to read the Registration Statement, including the preliminary proxy statement/prospectus and amendments thereto and the definitive proxy statement/prospectus and exhibits thereto, as well as other documents filed with the SEC in connection with the Business Combination, as these materials will contain important information about Altus Power, CBAH and the Business Combination. Information regarding CBAH’s directors and officers and a description of their interests in CBAH is contained in the Registration Statement.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements, which involve risks and uncertainties, relate to the use of proceeds for the new credit facility and analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to CBAH’s and Altus Power’s future prospects, developments and business strategies. In particular, such forward-looking statements include statements concerning the timing of the Business Combination, the business plans, objectives, expectations and intentions of CBAH once the Business Combination and the other transactions contemplated thereby (the “Transactions”) and change of name are complete (“New Altus”), and New Altus’s estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These statements are based on CBAH’s or Altus Power’s management’s current expectations and beliefs, as well as a number of assumptions concerning future events.

Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside CBAH’s or Altus Power’s control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Business Combination Agreement; (2) the inability to complete the Transactions due to the failure to obtain approval of the stockholders of CBAH or Altus Power or other conditions to closing in the Business Combination Agreement; (3) the ability of New Altus to meet NYSE’s listing standards (or the standards of any other securities exchange on which securities of the public entity are listed) following the Business Combination; (4) the inability to complete the private placement of common stock of CBAH to certain institutional accredited investors; (5) the risk that the announcement and consummation of the Transactions disrupts Altus Power’s current plans and operations; (6) the ability to recognize the anticipated benefits of the Transactions, which may be affected by, among other things, competition, the ability of New Altus to grow and manage growth profitably, maintain relationships with customers, business partners, suppliers and agents and retain its management and key employees; (7) costs related to the Transactions; (8) changes in applicable laws or regulations and delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals required to complete the Transactions; (9) the possibility that Altus Power and New Altus may be adversely affected by other economic, business, regulatory and/or competitive factors; (10) the impact of COVID-19 on Altus Power’s and New Altus’s business and/or the ability of the parties to complete the Transactions; (11) the outcome of any legal proceedings that may be instituted against CBAH, Altus Power, New Altus or any of their respective directors or officers, following the announcement of the Transactions; and (12) the failure to realize anticipated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions and purchase price and other adjustments.

Additional factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements can be found in the Registration Statement and CBAH’s proxy statement/prospectus when available. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and CBAH and Altus Power undertake no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.

This communication is not intended to be all-inclusive or to contain all the information that a person may desire in considering an investment in CBAH and is not intended to form the basis of an investment decision in CBAH. All subsequent written and oral forward-looking statements concerning CBAH and Altus Power, the Transactions or other matters and attributable to CBAH and Altus Power or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above.

Altus Power Contacts

For Media:
Cory Ziskind
ICR, Inc.
[email protected]

For Investors:
Caldwell Bailey
ICR, Inc.
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/altus-power-inc-a-market-leading-clean-electrification-company-announces-new-office-space-in-stamford-connecticut-to-accommodate-its-growing-team-301377038.html

SOURCE Altus Power, Inc.

Posted on

Autolus Therapeutics announces the appointment of John H. Johnson as non-executive chairman of its Board of Directors

LONDON, Sept. 15, 2021 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that John H. Johnson has been appointed as non-executive chairman of its Board of Directors, effective September 15, 2021. Dr. Martin Murphy, who previously served as chairman, will continue to serve as a non-executive Board member.

Mr. Johnson brings to Autolus more than 30 years of experience in the life science industry. He is currently chief executive officer and a director of Strongbridge Biopharma plc, a NASDAQ listed commercial stage biopharmaceutical company. He previously served as the executive chairman of the company from November 2019 to July 2020, and as chairman from March 2015 to November 2019. He is a recognized leader in the biopharmaceutical industry and has held executive, operations and commercial leadership roles at Eli Lilly & Company, ImClone, Johnson & Johnson, and Pfizer. He also currently serves as a member of the Board of Directors of Verastem, Inc and Axogen, Inc. Mr. Johnson previously served on the Board of Directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), BioNJ and holds a BS from the East Stroudsburg University of Pennsylvania.

“We are entering an exciting time in Autolus’ evolution as we progress obe-cel towards pivotal data and the expectation that obe-cel could become the first stand-alone therapy with curative potential for adult acute lymphoblastic leukemia (ALL) patients,” said Dr. Christian Itin, chief executive officer of Autolus. “Together with the entire board and management team I am delighted to welcome John as chairman of our Board. John’s experience in leading oncology-focused commercial-stage biopharmaceutical businesses will be invaluable as we start preparing for a successful outcome of the ongoing pivotal FELIX study of obe-cel.”

“I am delighted to serve as chairman of Autolus at such an important time in the Company’s development,” said John H. Johnson. “I am confident in Autolus’ ability to deliver its first pivotal data for its lead program in 2022 and am excited to work closely with the Board and Autolus’ experienced senior management team to develop therapies that may offer cancer patients substantial benefits over existing standards of care.”

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.

About Obe-cel 

Obe-cel is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. Designed to have a fast target binding off-rate to minimize excessive activation of the programmed T cells, Obe-cel may reduce toxicity and be less prone to T cell exhaustion, which could enhance persistence and improve the ability of the programmed T cells to engage in serial killing of target cancer cells. In collaboration with our academic partner, UCL, Obe-cel is currently being evaluated in a Phase 1 clinical trial in adult ALL and B-NHL. The company has also progressed Obe-cel to the FELIX study, a potential pivotal study.

About
Obe-cel
FELIX study

The FELIX Phase 1b/2 clinical trial is enrolling adult patients with relapsed / refractory ALL. The trial has a short Phase 1b component prior to proceeding to a single arm Phase 2 clinical trial. The primary endpoint is overall response rate, and the key secondary endpoints include duration of response, MRD negative CR rate and safety. The trial will enroll approximately 100 patients across 30 of the leading academic and non-academic centers in the United States, United Kingdom and Europe.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” and “believes.” These statements include, but are not limited to, statements regarding the future clinical development, efficacy, safety and therapeutic potential of obe-cel, including progress, expectations as to the reporting of data, conduct and timing and potential future clinical activity and milestones; expectations regarding the initiation, design and reporting of data from clinical trials. Any forward-looking statements are based on management’s current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus’ preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus’ business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus’ actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in Autolus’ Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 4, 2021, as well as discussions of potential risks, uncertainties, and other important factors in Autolus’ subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts:

Lucinda Crabtree, PhD
Vice President, Business Strategy and Planning
+44 (0) 7587 372 619
[email protected]

Julia Wilson
+44 (0) 7818 430877
[email protected]

Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
[email protected]



Posted on

Global-e Announces Closing of Secondary Offering of Shares

PETAH-TIKVA, Israel, Sept. 15, 2021 (GLOBE NEWSWIRE) — Global-e Online Ltd. (Nasdaq: GLBE) (the “Company” or “Global-e”), the world’s leading platform to enable and accelerate global, direct-to-consumer cross-border e-commerce, today announced the closing of its underwritten secondary offering by certain of its shareholders (the “Selling Shareholders”) of 13,800,000 of the Company’s ordinary shares at a price to the public of $64.00 per share (the “Offering”). The shares sold in the Offering included 1,800,000 shares sold following the exercise in full of the underwriters’ option to purchase additional ordinary shares. The Selling Shareholders received all of the proceeds from the Offering. Global-e did not sell any of its ordinary shares in the Offering and did not receive any proceeds from the Offering, including from the exercise by the underwriters of their option to purchase additional ordinary shares.

Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC, Jefferies LLC and BofA Securities, Inc. served as lead book-running managers for the Offering. Piper Sandler & Co., JMP Securities LLC, KeyBanc Capital Markets Inc., Needham & Company, LLC and Raymond James & Associates, Inc. served as co-managers for the Offering. The Offering was made only by means of a prospectus. A copy of the final prospectus relating to the Offering may be obtained from any of the following sources:

  • Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282, Attn: Prospectus Department, via telephone: 1-866-471-2526 or via email at [email protected];
  • Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, New York 10014, Attn: Prospectus Department;
  • Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022; by phone at (877) 821-7388; or by e-mail at [email protected];
  • BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte NC 28255-0001, Attn: Prospectus Department, or via email at [email protected].

A registration statement on Form F-1 relating to these securities was declared effective by the SEC on September 9, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Global-e

Global-e is the world’s leading platform to enable and accelerate global, direct-to-consumer cross-border e-commerce. The chosen partner of more than 520 global brands and retailers across the United States, Europe and Asia, Global-e makes selling internationally as simple as selling domestically. Founded in 2013 by Amir Schlachet, Shahar Tamari and Nir Debbi, the company enables e-commerce retailers to increase the conversion of international traffic into sales by offering online shoppers in over 200 destinations worldwide a seamless, localized shopping experience. Global-e’s end-to-end e-commerce solutions combine best-in-class localization capabilities, big-data best-practice business intelligence models, streamlined international logistics and vast cross-border experience, enabling international shoppers to buy seamlessly online and retailers to sell from, and to, anywhere in the world.

Forward‐Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “intend,” “expect,” and “may,” and other similar expressions that predict or indicate future events or that are not statements of historical matters. Forward-looking statements are based on current information available at the time the statements are made and on management’s reasonable belief or expectations with respect to future events, and are subject to risks and uncertainties, many of which are beyond the Company’s control, that could cause actual performance or results to differ materially from the belief or expectations expressed in or suggested by the forward-looking statements. Additional factors or events that could cause actual results to differ may also emerge from time to time, and it is not possible for the Company to predict all of them. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement to reflect future events, developments or otherwise, except as may be required by applicable law. Investors are referred to the Company’s registration statement for additional information regarding the risks and uncertainties that may cause actual results to differ materially from those expressed in any forward-looking statement.

Press Contact:

Headline Media
Garrett Krivicich
[email protected]
+1 786 233 7684

Investor Contact:

Erica Mannion or Mike Funari
Sapphire Investor Relations, LLC
[email protected]
+1 617-542-6180



Posted on

Calavo Growers Appoints Amazon Executive Mariela Matute as CFO

SANTA PAULA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Calavo Growers, Inc. (Nasdaq-GS: CVGW), a global leader in the avocado and value-added fresh food industries, today announced that Mariela Matute has been appointed Chief Financial Officer, effective October 11, 2021.

“We are excited to welcome Mariela Matute as an integral member of our management team,” said Steven Hollister, interim Chief Executive Officer of Calavo Growers. “Mariela has an impressive combination of financial expertise and relevant industry background, including food production and agriculture, which make her highly qualified to assume the role of CFO. She is a proven senior financial leader, joining us most recently from her role as CFO of the B2B division of Amazon. In addition, she also has deep experience and exposure to Mexico and Latin America, having served as CFO of Driscoll’s Americas region, which spanned from Canada to Chile. Her broad skill set will benefit the company and all its many stakeholders.”

“I am thrilled to step into the CFO role at Calavo and to help the company execute its strategic plan, accelerate its profitable growth and deliver shareholder value. I look forward to partnering with the entire Calavo team to build on the company’s strong foundation,” said Ms. Matute.

On behalf of the Board of Directors, J. Link Leavens added, “I also want to thank Farha Aslam for having served as interim CFO and for making this transition such a smooth one. We look forward to her many contributions now that she has returned to her role as independent director.”

Professional Background of Mariela Matute

Prior to joining Calavo, Ms. Matute most recently served as Director and Chief Financial Officer for Amazon Business, the business-to-business (B2B) online procurement division of Amazon.com, Inc. (NYSE: AMZN), where she managed a team of 70 professionals across controllership, financial planning, pricing analytics, sales and operations planning, tech roadmap and payments. Also at Amazon, she served as Director of Finance and Operations for its Amazon Fresh division. Prior to that role, she was Vice President, Finance and CFO of The Americas Region for Driscoll’s Inc., a global market leader of fresh berries, where she was responsible for treasury, finance, IT, real estate and procurement. Before that, Ms. Matute held financial leadership positions at The Chia Company (the world’s largest producer of Chia seed), Henkel Corp. (a German chemical and consumer goods company), Alcoa Corporation, and Pitney Bowes. She began her career in Latin America with Procter & Gamble.

Ms. Matute has a BSc in industrial engineering from Universidad Catolica Andres Bello (Venezuela) and an MBA from the University of Michigan.

About Calavo Growers, Inc.

Calavo Growers, Inc. is a global avocado-industry leader and provider of value-added fresh food serving retail grocery, foodservice, club stores, mass merchandisers, food distributors and wholesalers worldwide. The Company’s Fresh segment procures and markets fresh avocados and select other fresh produce, including tomatoes and papayas. The Renaissance Food Group (RFG) segment creates, markets and distributes a portfolio of healthy fresh foods, including fresh-cut fruit, fresh-cut vegetables and prepared foods. The Foods segment manufactures and distributes guacamole and salsa. Founded in 1924, Calavo’s fresh food products are sold under the respected Calavo brand name as well as Garden Highway, Chef Essentials and several private label and store brands.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/59aec5d1-f869-44f9-bb4b-88978ad94efd

Contact: Financial Profiles, Inc.
Lisa Mueller, Senior Vice President
(310) 622-8231
[email protected]



Posted on

IVECO and Nikola inaugurate joint-venture manufacturing facility for electric heavy-duty trucks in Ulm, Germany

The partnership between the global commercial
vehicles
manufacturer and the US-based group specializing in zero-emission
Class 8
heavy-duty trucks and related energy solutions is about to begin its manufacturing journey in Ulm, Germany.

Ulm, September 15, 2021

An exciting new chapter in IVECO and Nikola Corporation’s sustainable transport story set course today in Ulm, Germany as the manufacturing facility dedicated to the Nikola Tre electric heavy-duty trucks was unveiled to the public, ready to start production by year end. A milestone reached at record speed and delivered on schedule as previously communicated by IVECO, the commercial vehicles brand of CNH Industrial (NYSE: CNHI / MI: CNHI), and Nikola Corporation (NASDAQ: NKLA). The first Nikola Tre models produced here will be delivered to select customers in the United States in 2022. In addition to the battery-electric vehicle (BEV) production model, the next evolution of this modular heavy-duty platform was also on display to the public in the form of the fuel cell electric vehicle (FCEV) prototype of the Nikola Tre. This subsequent model will enter production in Ulm by the end of 2023.

Today’s launch event was hosted in accordance with current COVID-19 standards and was limited to a select gathering of about 100 international and national stakeholders and media. Among those in attendance were Gerrit Marx, President Commercial & Specialty Vehicles at CNH Industrial and designated CEO of the Iveco Group; Mark Russell, Chief Executive Officer and President of Nikola; Winfried Herrmann, State Minister of Transport in Baden-Württemberg; Martin Bendel, First Mayor of the city of Ulm; Massimiliano Lagi, Consul General of Italy in Stuttgart, Germany.

“Despite all the industry and global pandemic challenges we have been facing since we first announced this partnership in September 2019, it is extremely rewarding to be able to stand here today as a team and witness the execution of all of our hard work delivered on time and according to our original plans,” said Gerrit Marx during his opening address. “Thanks to IVECO’s proven expertise and established footprint we have provided a platform upon which Nikola’s technology can thrive. Now our focus is on ensuring the success of this operation and jointly taking the lead when it comes to climate-neutral long- and short-haul heavy-duty transport.”

Spanning 50,000 square meters, of which 25,000 are covered, the Ulm manufacturing facility features a final assembly process that has been designed for “electric-born” vehicles. This site, and first phase of industrialization, represents joint investment by IVECO and Nikola and involves a projected 160 suppliers in the process from start to finish. The production line is currently anticipated to be capable of manufacturing approximately 1,000 units per shift per year and is expected to undergo progressive ramp-up in the following years. The site is expected to operate according to the principles of the World Class Manufacturing programme, with the goal of achieving zero waste, zero accidents, zero failures and zero stock, confirmed by its key characteristics which include fully digital shopfloor management designed to guarantee 100% traceability and paperless operations.

“This new facility is beautiful, and we are grateful to the IVECO and Nikola teams for their collaboration and perseverance to bring it to life,” said Nikola CEO Mark Russell. “This is yet another important milestone for Nikola as we execute on our strategy and vision to be a global leader in zero-emissions transportation solutions.”

Designed and projected as a safe, reliable and high-performance, zero-emission transport solution, the Nikola Tre is driving change for the sector. Based on the IVECO S-WAY truck platform with an electric axle co-designed and produced by FPT Industrial, it features Nikola’s advanced electric and fuel cell technology, along with key components provided by Bosch. Together, the teams have designed a modular platform capable of fuel cell as well as battery propulsion technology. Launching the battery technology first will drive the maturity of the underlying platform before adding the fuel cell as a range-extension technology.


CNH Industrial


N.V.

(NYSE: CNHI /
M
I
: CNHI) is a global leader in the capital goods sector with established industrial experience, a wide range of products and a worldwide presence. Each of the individual brands belonging to the Company is a major international force in its specific industrial sector: Case IH, New Holland Agriculture and
Steyr
for tractors and agricultural machinery; Case and New Holland Construction for earth moving equipment
; Iveco for commercial vehicles; Iveco Bus and
Heuliez
Bus for buses and coaches; Iveco Astra for quarry and construction vehicles;
Magirus
for firefighting vehicles; Iveco
Defence
Vehicles for
defence
and civil protection; and FPT Industrial for engines and transmissions.
More information can be found on the corporate website:

www.cnhindustrial.com


Nikola Corporation

(N
ASDAQ
: NKLA) is globally transforming the transportation industry. As a designer and manufacturer of zero-emission battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen station infrastructure, Nikola is driven to revolutionize the economic and environmental impact of commerce as we know it today. Founded in 2015, Nikola Corporation is headquartered in Phoenix, Arizona. For more information, visit

www.nikolamotor.com

or Twitter

@nikolamotor

.


FORWARD LOOKING STATEMENTS


Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential benefits of the joint-venture relationship between Nikola and CNHI/IVECO; the ability to hit the expected delivery timelines for the BEV and FCEV vehicles; the manufacturing capabilities and standards of the new joint-venture manufacturing facility; the joint-venture’s ability to assemble fuel-cell power modules at the new manufacturing facility; the expected benefits from integrating the S-Way truck platform with electric vehicle technology; expectations regarding its business, business model and strategy; the company’s expectations for its trucks and market acceptance of electric trucks, both BEV and FCEV; and market opportunity. These statements are based on various assumptions,
whether or not
identified in this press release, and on the current expectations of Nikola’s management and are not predictions of actual performance. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements, including but not limited to, design and manufacturing changes and delays; failure to realize the anticipated benefits of the definitive agreements; general economic, financial, legal, regulatory, political and business conditions and changes in domestic and foreign markets; the potential effects of COVID-19; the outcome of legal, regulatory and judicial proceedings to which Nikola is, or may become a party; demand for and customer acceptance of Nikola’s trucks; risks associated with development and testing of fuel-cell power modules and hydrogen storage systems; risks related to the rollout of Nikola’s business and the timing of expected business milestones; the effects of competition on Nikola’s future business; the availability of capital; risks associated with changes in accounting treatment or accounting standards; and the other risks detailed from time to time in Nikola’s reports filed with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended June 30, 2021 and other documents Nikola files with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. These forward-looking statements speak only as of the date hereof and Nikola specifically disclaims any obligation to update these forward-looking statements.

Sign up for corporate news alerts from the CNH Industrial Newsroom:


bit.ly/media-


cnhindustrial


-subscribe

Media
contact
s
:

Francesco Polsinelli
Corporate Communications Manager, Europe
CNH Industrial
Tel.: +39 335 1776091        

Email: [email protected]
www.cnhindustrial.com

Nicole Rose
Nikola Corporation
Tel.: +1 480-660-6893
[email protected]
www.nikolamotor.com

Colleen Robar
Nikola Corporation
Tel.: +1 313-207-5960
[email protected]
www.nikolamotor.com

Attachments



Posted on

Immunovant Appoints Renee Barnett as Chief Financial Officer

  • Ms. Barnett brings a wealth of financial experience to Immunovant
  • Expands executive leadership team as Immunovant plans to return to the clinic across multiple indications

NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021.

“We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company,” said Pete Salzmann, M.D., Chief Executive Officer. “Renee brings a deep understanding of drug development and strategic financial management. She has consistently delivered outstanding results over the course of her career and thrives in dynamic, high-growth environments. As our team expands and we accelerate the development of batoclimab (IMVT-1401), Renee’s wealth of financial and executive experience will be invaluable.”

With two decades of experience in healthcare, Ms. Barnett began her career at Eli Lilly where she developed expertise in strategic financial leadership across the drug development life cycle through to commercialization, both in the US and in Europe. During her tenure at Lilly her roles included CFO of Lilly Austria and Switzerland as well as global lead for Financial Planning and Analysis, which included support of executive financial reporting and investor relations. More recently, Ms. Barnett served in a variety of executive-leadership functions at AbleTo, Inc., a technology-enabled healthcare service provider focused on virtual delivery of behavioral healthcare. Ms. Barnett’s roles at AbleTo included VP Finance and acting CFO, SVP Operations, and most recently Chief Integration Officer, a position in which she was responsible for leading AbleTo’s enterprise-wide digital transformation.

Ms. Barnett joins Immunovant as the company prepares to initiate a pivotal trial in myasthenia gravis (MG) as well as reinitiate its programs in thyroid eye disease (TED) and warm autoimmune hemolytic anemia (WAIHA). The company also plans to initiate trials in two additional indications based on regulatory alignment. “I am thrilled to join the Immunovant team at such an exciting and critical time as Immunovant leverages its strong financial position to advance the development of batoclimab across multiple indications with many opportunities to help enable normal lives for people with autoimmune diseases,” said Ms. Barnett.

Ms. Barnett holds an MBA from Harvard Business School and a BA in Physics from DePauw University.

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. 

Forward-Looking Statements

This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “plan,” “might,” “will,” “would,” “should,” “expect,” “believe,” “estimate,” and other similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning Immunovant’s plans to return to the clinic and reinitiate trials in MG, WAIHA and TED and initiate additional clinical studies in at least two other indications based on regulatory alignment, the ability of Immunovant to identify new opportunities, the potential efficacy and success of IMVT-1401 and the potential of IMVT-1401 to become a best-in-class treatment for multiple autoimmune diseases and to improve the quality of life for patients suffering from these conditions. All forward-looking statements are based on estimates and assumptions by Immunovant’s management that, although Immunovant believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Immunovant expected. Such risks and uncertainties include, among others, initial results or other preliminary analyses or results of early clinical trials may not be predictive final trial results or of the results of later clinical trials; the availability of data from clinical trials; the expectations for regulatory submissions and approvals; the continued development of Immunovant’s product candidates; Immunovant’s scientific approach and general development progress; the availability and commercial potential of Immunovant’s product candidates including the size of potentially addressable markets and degree of market acceptance; and the potential impact of the COVID-19 pandemic on Immunovant’s clinical development plans and timelines. These and other risks and uncertainties are more fully described in Immunovant’s periodic and other reports filed with the Securities and Exchange Commission (SEC), including in the section titled “Risk Factors” in Immunovant’s most recent Quarterly Report on Form 10-Q filed with the SEC on August 9, 2021. Any forward-looking statement speaks only as of the date on which it was made. Immunovant undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
[email protected]

 



Posted on

Skylight Health Group Enters New State Acquiring Pennsylvania Clinic Group Aspire Health Concepts

  • Skylight is acquiring a controlling interest in Pennsylvania-based Aspire Health Concepts, Inc., operating a network of 2 clinics servicing over 10,000 patients annually including over 2,000 Medicare and Medicare Advantage lives.
  • Company expects to enroll the eligible Medicare lives in its first value-based care performance year of 2022.
  • Company expects incremental annualized revenue of over US$2.5 million with 8% EBITDA.
  • Immediately accretive acquisition strengthens Company’s growing primary care patient base, increases national footprint, and adds 14 providers to Skylight Health.
  • Company expects to see further opportunities to build density in Pennsylvania through acquisition and de novo.

TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) — Skylight Health Group Inc. (NASDAQ:SLHG; TSXV:SLHG) (“Skylight Health”, “Skylight” or the “Company”), a multi-state primary care management group in the United States, today announces execution of definitive agreements to acquire a controlling interest in Aspire Health Concepts, Inc. (“Aspire”), a primary care group in Pennsylvania with 2 locations. The acquisition expands the Company’s primary care services into a new state and grows its patient base by over 10,000 per year.

Aspire has been operating a multi-disciplinary network of clinics for over 12 years in Harrisburg, PA. Skylight will immediately take over the primary and urgent care components of the business. The acquisition is immediately accretive to the Company as it expands its market share into a new state with an established patient base. Skylight expects full continuity of the Aspire leadership and clinical teams post-acquisition.

Prad Sekar, CEO, Skylight said “This is a very exciting acquisition for us. Skylight enters a new market with a clinic group that is well established and well regarded, at a time when growth in the primary care sector is strong and patients are seeking a higher level of care. As we continue to integrate our growing number of clinics across the US, the Aspire acquisition is certainly an excellent fit to the Skylight family.”

“We’ve spent the last 12 years building strong relationships with our patients in eastern Pennsylvania, and we’re proud and excited to align ourselves with Skylight as we now transition our patients to an even more comprehensive healthcare model,” said Dr. David A. White, MD. and Dr. Richard Rayner, MD., Founders of Aspire. “We fully support the Skylight executive and leadership team, and believe that with their centralized services and technology, they have the tools and vision for us to take this business to the next level.”

The Company has acquired a controlling interest of 70% of Aspire. The remaining 30% of Aspire will be retained by the two Founding physicians subject to Skylight’s call option that matures on the five-year anniversary of the closing. Skylight expects this structure will enhance alignment between Skylight and the Founding physicians. The Company expects to close this transaction no later than September 17th.

ABOUT SKYLIGHT HEALTH GROUP INC.

Skylight Health Group (NAQSAQ:SLHG; TSXV:SLHG) is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The Company is focused on helping small and independent practices shift from a traditional fee-for-service (FFS) model to value-based care (VBC) through tools including proprietary technology, data analytics and infrastructure. In a FFS model, payors (commercial and government insurers) reimburse on an encounter-based approach. This puts a focus on volume of patients per day. In a VBC model, payors reimburse typically on a capitation (fixed fee per member per month) basis. This places an emphasis on quality over volume. VBC will lead to improved patient outcomes, reduced cost of delivery and drive stronger financial performance from existing practices.

For more information, please visit www.skylighthealthgroup.com or contact:

Investor Relations:

Canadian Investors

Jackie Kelly 
[email protected] 
416-301-2949

U.S. Investors

John Evans
[email protected]
415-309-0230

Currency Usage, Cautionary and Forward-Looking Statements

All currency contained in this Press Release represent Canadian Dollars unless otherwise stated.

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Skylight Health’s filings with Canadian and United States securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.

Although Skylight Health has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: the ability of Skylight Health to execute on its business strategy, continued revenue growth in accordance with management’s expectations, operating expenses continuing in accordance with management expectations, dependence on obtaining regulatory approvals; Skylight Health being able to find, complete and effectively integrate target acquisitions; change in laws relating to health care regulation; reliance on management; requirements for additional financing; competition; hindering market growth or other factors that may not currently be known by the Company.

There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Skylight Health disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Skylight Health does not assume any liability for disclosure relating to any other company mentioned herein.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.